Home Cart Sign in  
Chemical Structure| 201002-47-3 Chemical Structure| 201002-47-3
Chemical Structure| 201002-47-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Fmoc-D-Lys-OH·HCl is a protected D-lysine derivative with the amino group protected by 9-fluorenylmethoxycarbonyl (Fmoc), in hydrochloride form, suitable for peptide synthesis.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Christopher DeNyse ;

Abstract: Breast cancer (BrCa) is a pressing health concern, necessitating the development of effective imaging and therapeutic agents. To address this need, we designed and synthesized molecularly targeted imaging and therapeutic agents that combine visualization and treatment of tumors in real-time. Our approach involved the development of dual-modal agents, incorporating the fluorescent near infrared (NIR) dye, IRDye78, and a chlorin-based photosensitizer (PS) dye, Mesopyropheoborbide-a (mPPa), coupled to a BrCa-targeting peptide," 18-4." Additionally, we created a water-soluble, single-modal targeted PS probe for photodynamic therapy (PDT) of BrCa for use guided by other imaging methods. Our methodology was based on a modular approach, wherein modules containing the dyes attached to a lysine scaffold were utilized to attach the dye payloads in two different combinations: one with the PS dye on the lysine side chain and fluorescent dye, IRDye78, on the n-terminus of lysine, and the other with reversed positions of the two dyes. Furthermore, we extended this method to synthesize palladium-metalated versions of these modules. For the water-soluble, targeted single-modal probe, we designed a module that incorporated the PS dye on the side chain of lysine, attached to a water-solubilizing tri-sulfonated arm on the n-terminus. This module was then coupled to the BrCa peptide, resulting in a single_x005f_x0002_modal PS for PDT of BrCa. Two probes were provided to the University of Rochester for evaluation in BrCa cells and murine models. Preliminary results confirmed the uptake of our first dual modal probe into BrCa cells through fluorescent microscopy. This work represents the first example of receptor-targeted, dual-modal imaging and therapy agents for combined imaging and PDT of BrCa. Additionally, a new approach to water-soluble, single-modal targeted PDT agent is introduced. Overall, this comprehensive approach offers hope for improved outcomes in lumpectomy and represents a substantial advancement in the fight against breast cancer.

Purchased from AmBeed: ;

Alternative Products

Product Details of Fmoc-D-Lys-OH·HCl

CAS No. :201002-47-3
Formula : C21H25ClN2O4
M.W : 404.89
SMILES Code : O=C(O)[C@H](NC(OCC1C2=C(C3=C1C=CC=C3)C=CC=C2)=O)CCCCN.[H]Cl
MDL No. :MFCD00190888
InChI Key :MVMZFAIUUXYFGY-FSRHSHDFSA-N
Pubchem ID :44629939

Safety of Fmoc-D-Lys-OH·HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338
 

Historical Records

Technical Information

Categories